Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/14294
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Weecharangsan W. | |
dc.contributor.author | Lee R.J. | |
dc.date.accessioned | 2021-04-05T03:34:01Z | - |
dc.date.available | 2021-04-05T03:34:01Z | - |
dc.date.issued | 2012 | |
dc.identifier.issn | 10717544 | |
dc.identifier.other | 2-s2.0-84866256041 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/14294 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866256041&doi=10.3109%2f10717544.2012.714810&partnerID=40&md5=49c52723b72986b90604e875f73414ff | |
dc.description.abstract | Previous study has shown human serum albumin (HSA) coated liposomes can deliver bcl-2 antisense oligodeoxyribonucleotide (ODN) into KB carcinoma cells, and decrease bcl-2 mRNA and protein expression level. In the current study, cell growth inhibition and chemosensitization of KB cells were evaluated. Liposomes composed of dimethyldioctadecyl ammonium bromide/egg phosphatidylcholine/ α-tocopheryl polyethylene glycol 1000 succinate (58:40:2 molar ratio) complexed with bcl-2 antisense ODN and coated with HSA were examined for cell growth inhibition and sensitization to a commonly used chemotherapeutic drug, doxorubicin. HSA-coated liposomeODN complexes effectively inhibited cell growth in the range of ODN concentration of 0.457.2 M. Upon posttreatment with doxorubicin, the cytotoxicity was further significantly increased compared to the ODN complexes alone. The cytotoxicity was dependent on antisense ODN concentration, incubation time and doxorubicin concentration, and relatively independent on HSA concentration. This study suggests that HSA-coated liposomes are effective delivery vehicles for antisense ODN with potential therapeutic application and can be effectively combined with doxorubicin. © 2012 Informa Healthcare USA, Inc. | |
dc.subject | alpha tocopheryl polyethylene glycol 1000 succinate | |
dc.subject | antisense oligodeoxynucleotide | |
dc.subject | dimethyldioctadecyl ammonium bromide | |
dc.subject | doxorubicin | |
dc.subject | egg phosphatidylcholine | |
dc.subject | human serum albumin | |
dc.subject | liposome | |
dc.subject | messenger RNA | |
dc.subject | protein bcl 2 | |
dc.subject | unclassified drug | |
dc.subject | article | |
dc.subject | carcinoma cell | |
dc.subject | cell growth | |
dc.subject | cell strain KB | |
dc.subject | chemosensitization | |
dc.subject | concentration response | |
dc.subject | controlled study | |
dc.subject | cytotoxicity | |
dc.subject | drug coating | |
dc.subject | drug delivery system | |
dc.subject | genetic transfection | |
dc.subject | growth inhibition | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | incubation time | |
dc.subject | mouth carcinoma | |
dc.subject | priority journal | |
dc.subject | protein expression | |
dc.subject | Antibiotics, Antineoplastic | |
dc.subject | Cell Growth Processes | |
dc.subject | Cell Line, Tumor | |
dc.subject | Dose-Response Relationship, Drug | |
dc.subject | Doxorubicin | |
dc.subject | Gene Expression Regulation, Neoplastic | |
dc.subject | Humans | |
dc.subject | KB Cells | |
dc.subject | Lipids | |
dc.subject | Liposomes | |
dc.subject | Mouth Neoplasms | |
dc.subject | Oligodeoxyribonucleotides, Antisense | |
dc.subject | Proto-Oncogene Proteins c-bcl-2 | |
dc.subject | RNA, Messenger | |
dc.subject | Serum Albumin | |
dc.subject | Time Factors | |
dc.title | Growth inhibition and chemosensitization of human carcinoma cells by human serum albumin-coated liposomal antisense oligodeoxyribonucleotide against bcl-2 | |
dc.type | Article | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Drug Delivery. Vol 19, No.6 (2012), p.292-297 | |
dc.identifier.doi | 10.3109/10717544.2012.714810 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.